Lucid Diagnostics Inc.
Develops a non-invasive DNA test for the early detection of esophageal precancer.
LUCD | US
Overview
Corporate Details
- ISIN(s):
- US54948X1090
- LEI:
- Country:
- United States of America
- Address:
- 360 MADISON AVENUE, 10017 NEW YORK
- Website:
- https://www.luciddx.com/
- Industry:
- Other human health activities
Description
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the prevention of esophageal cancer. The company's primary product is the EsoGuard Esophageal DNA Test, a non-invasive diagnostic tool designed for the early detection of esophageal precancer, including Barrett's esophagus. Utilizing targeted next-generation sequencing (NGS) technology, EsoGuard analyzes DNA biomarkers from cells collected in a simple, office-based procedure. This allows for the screening of at-risk patients, such as those with chronic gastroesophageal reflux disease (GERD), without the need for an initial endoscopy. The company aims to improve patient outcomes by identifying precancerous conditions at a treatable stage, thereby preventing the progression to esophageal adenocarcinoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lucid Diagnostics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lucid Diagnostics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lucid Diagnostics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
